Pharma Has History of Price Gouging, Mylan Should Be No Surprise

Pharma Has History of Price Gouging, Mylan Should Be No Surprise

Pharmacy Benefit Managers Shouldn't Fret Initial Fallout from Mylan Fiasco

Pharmacy Benefit Managers Shouldn't Fret Initial Fallout from Mylan Fiasco

Investors Can't Count on This Bonus From Pharma Deals

Investors Can't Count on This Bonus From Pharma Deals

Andrew Left Says Mallinckrodt's Key Drug Could Be in Jeopardy

Andrew Left Says Mallinckrodt's Key Drug Could Be in Jeopardy

Mylan's EpiPen Price Increase Is a Reason to Stay Clear of the Company

Mylan's EpiPen Price Increase Is a Reason to Stay Clear of the Company

Mylan to Offer Savings Card on EpiPen After Controversial 400% Price Increase

Mylan to Offer Savings Card on EpiPen After Controversial 400% Price Increase

4 Stocks for Fighting Zika

4 Stocks for Fighting Zika

Mallinckrodt Could Be Next in Spotlight Thanks to EpiPen Scrutiny

Mallinckrodt Could Be Next in Spotlight Thanks to EpiPen Scrutiny

Futures Lower Following Clinton EpiPen Tweet; Asia Opens Down Too

Futures Lower Following Clinton EpiPen Tweet; Asia Opens Down Too

Gilead Sciences Shares Slide on Leerink Price Target Cut

Gilead Sciences Shares Slide on Leerink Price Target Cut